CLINICAL STAGE LICENSING OPPORTUNITY  INHALED DRUG FOR COPD (CHRONIC  OBSTRUCTIVE PULMONARY DISEASE)   (PAH)

www.therametrics.com CLINICAL STAGE LICENSING OPPORTUNITY AVIPTADIL INHALED DRUG FOR COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) DK‐1000 (PAH)
AVIPTADIL EFFICACY & SAFETY • Regulatory approved drug for a different indication with excellent safety profile. • Complete preclinical package for acute and chronic inhaled administration in pulmonary indications available, with excellent safety profile. • Clinical stage compound for pulmonary indications in Europe and USA. • Inhibits the overly induced inducible NO synthase expression. • Positively regulates the endothelial NO synthase expression. • Inhibits inflammation (IL‐8, MCP‐1, IP‐10, MIP‐1 alpha, CCL5, TNF alpha, IL‐6, IL‐12, IL‐17). • Induces physiological remodelling. • Induces IL‐10. ADVANTAGES vs. CURRENT STANDARD OF CARE • Aviptadil is a crucial human lung homeostatic factor; it is severely diminished in COPD, and this paucity is one of the major reasons for COPD pathology. • Current treatments for COPD address the bronchoconstriction and inflammation, but NOT the Aviptadil paucity in COPD. • Aviptadil can act alone, or in combination with any other approved COPD treatment option, with excellent safety profile. GLOBAL MARKET POTENTIAL IN EXCESS OF $12 Billion MARKETING APPROVAL EXPECTED IN AROUND 3 YEARS THERAMetrics is seeking partners for the global commercialization of AVIPTADIL (DK‐1000) in COPD. INTELLECTUAL PROPERTY & PATENTS COPD • Global patent coverage: Issued and validated patents in USA, UK, France, Germany, Italy, Turkey, China, Mexico, India, Switzerland, Spain, Netherlands, Sweden, Belgium, Denmark, Ireland, Austria & Australia. • Expiration date no earlier than 2026. • Formulation & second medical use patents. CLINICAL DEVELOPMENT • COPD is characterized by chronically poor airflow. It typically worsens over time. The main symptoms include shortness of breath, cough, and sputum production. It affects more than 300 million people or nearly 5% of the global population. • It ranks as the fourth leading cause of death. • Phase II drug for Europe and USA, with available drug material for Phase III. • Upside potential in Sarcoidosis, Pulmonary Hypertension, Cystic Fibrosis, and via injection in Acute Lung Injury. • There is no known cure for COPD, but the symptoms are treatable and its progression can be delayed by Inhaled bronchodilators (β2 agonists and anticholinergics), and Corticosteroids. Headquartered in Stans, Switzerland, THERAMetrics is a Tech Contract Research & Development Organization offering full
competitive technological solutions through the entire value chain of drug discovery & development and innovative
partnerships/alliances business opportunities to Biopharma companies.
For further information, please visit us at www.therametrics.com